Nephrology

Vasculitis

Questions discussed in this category

How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?

1 Answer available

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

2 Answers available

Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?

1 Answer available

How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?

1 Answer available

Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?

2 Answers available

What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?

2 Answers available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

2 Answers available

Would you check ANCA titers in a patient with a history of PR-3-ANCA glomerulonephritis in remission and a stable creatinine but with recurrent microscopic hematuria?

6 Answers available

How do you approach relapsing ANCA-associated vasculitis in a patient who has already undergone kidney transplant?

1 Answer available

Papers discussed in this category

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Current opinion in rheumatology, 2018 Jul

Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.

European journal of medical research, 2009 Dec 07

Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.

Annals of the rheumatic diseases, 2018 Jun 27

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Annals of the rheumatic diseases, 2024 Jan 11

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08

Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.

Current medical research and opinion, 2016-12

Corticosteroids: the knee jerk response.

Related Topics in Nephrology